drugset / Trial / NCT00847860

Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions

NCT00847860

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of PDE-3 inhibitor, cilostazol, in prevention and treatment of vascular dementia, in those with brain white matter lesions and vascular risk factors.

Timeline

Start
2008-03
Primary completion
2011-05
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 100 mg
Subject Cilostazol Small molecule 100 mg